Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes

Abstract

AbstractIntroductionAcquired haemophilia A (AHA) is a bleeding disorder caused by autoantibody development against factor VIII (FVIII). Studies on AHA have mainly focused on patients treated at specialist centres.AimTo determine the incidence, clinical characteristics and outcomes of AHA in an unselected population‐based patient cohort from Finland.MethodsThis retrospective observational cohort comprised all cases diagnosed with AHA in Finland between 2006 and 2019. Patients were identified by the two central laboratories performing FVIII antibody testing in Finland, the Finnish Red Cross Blood Service and HUSLAB. Clinical details were collected from all hospitals and healthcare units where patients were treated. This study was performed in conjunction with the AHA in the Nordics study.ResultsThe median incidence of AHA was 0.65 per million per year (range 0.19‐1.27). Fifty‐five patients were identified, with a median age of 76 years and an even sex ratio (51% women). When diagnosed, all had bleeding symptoms with severe bleeds in 92%. First‐line immunosuppressive treatment regimens included steroid monotherapy in 31% of cases, steroids and a cytotoxic agent in 51% and a rituximab‐based regimen in 16%. Clinical remission was achieved in 71% of cases, and 15% had relapses. Mortality was 13% for bleeds and 9% for treatment‐related infections. Overall survival was 64% for 1 year and 56% for 2 years after diagnosis.ConclusionsIn a nationwide population‐based cohort study, we discovered a lower incidence of AHA than previously reported. Mortality among patients with AHA was high, calling for the consideration of updated treatment strategies.